GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The N-methyl-d-aspartate receptor-ionophore complex plays a key role in learning and memory and has efficacy in animals and humans with affective disorders. GLYX-13 is an N-methyl-d-aspartate receptor (NMDAR) glycine-site functional partial agonist and cognitive enhancer that also shows rapid antidepressant activity without psychotomimetic side effects. AREAS COVERED: The authors review the mechanism of action of GLYX-13 that was investigated in preclinical studies and evaluated in clinical studies. Specifically, the authors review its pharmacology, pharmacokinetics, and drug safety that were demonstrated in clinical studies. EXPERT OPINION: NMDAR full antagonists can produce rapid antidepressant effects in treatment-resistant subjects; however, they are often accompanied by psychotomimetic effects that make chronic use outside of a clinical trial inpatient setting problematic. GLYX-13 appears to exert its antidepressant effects in the frontal cortex via NMDAR-triggered synaptic plasticity. Understanding the mechanistic underpinning of GLYX-13's antidepressant action should provide both novel insights into the role of the glutamatergic system in depression and identify new targets for therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“GLYX-13 did not cause any increase in suicidality over the course of the 14- or 28-day course of observation following dosing (Figure 5B) using the Columbia-Suicide Severity Rating Scale [64].”
MethodMalenka, R. C., & Bear, M. F. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.012 · Cited by 3,968
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 1×
“NMDARs exist in multiple subtypes -- at least 12 functionally distinct ones have been characterized to date, and are developmentally regulated and differentially distributed in various brain regions [1-7].”
BackgroundMonyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 1×
“NMDARs exist in multiple subtypes -- at least 12 functionally distinct ones have been characterized to date, and are developmentally regulated and differentially distributed in various brain regions [1-7].”
BackgroundBienenstock, E., Cooper, L., & Munro, P. (1982) · The Journal of Neuroscience · doi:10.1523/jneurosci.02-01-00032.1982 · Cited by 2,896 · cited 1×
“NMDAR activation is a key component of both the induction of LTP and of metaplastic regulation of the threshold for future LTP [8,44-50].”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 3×
“Interestingly, it has been shown that GSK-3b plays a key role in regulating one form of synaptic plasticity, LTD [55,56].”
BackgroundMethodSynaptic Plasticity and Memory: An Evaluation of the Hypothesis
Martin, S. J., Grimwood, P. D., & Morris, R. G. M. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.649 · Cited by 2,794 · cited 1×
“plasticity believed to be necessary for learning and memory formation [9-18].”
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523 · cited 1×
“NMDARs exist in multiple subtypes -- at least 12 functionally distinct ones have been characterized to date, and are developmentally regulated and differentially distributed in various brain regions [1-7].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“Interestingly, it has been shown that GSK-3b plays a key role in regulating one form of synaptic plasticity, LTD [55,56].”
BackgroundLearning induces long-term potentiation in the hippocampus
Whitlock, J. R., Heynen, A. J., Shuler, M. G., & Bear, M. F. (2006) · Science · doi:10.1126/science.1128134 · Cited by 1,913 · cited 1×
“plasticity believed to be necessary for learning and memory formation [9-18].”
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 1×
“The version of the Porsolt test used has been shown to have high sensitivity and specificity for detecting the antidepressant effects of drugs [40], and the versions of the NIH and LH tests used require chronic administration of typical antidepressants such as fluoxetine to show efficacy but can detect the acute and l…”
MethodChanging subunit composition of heteromeric NMDA receptors during development of rat cortex
Sheng, M., Cummings, J., Roldan, L. A., Jan, Y. N., & Jan, L. Y. (1994) · Nature · doi:10.1038/368144a0 · Cited by 1,377 · cited 1×
“NMDARs exist in multiple subtypes -- at least 12 functionally distinct ones have been characterized to date, and are developmentally regulated and differentially distributed in various brain regions [1-7].”
BackgroundMaking memories last: the synaptic tagging and capture hypothesis
Redondo, R. L., & Morris, R. G. M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2963 · Cited by 792 · cited 1×
“NMDAR activation is a key component of both the induction of LTP and of metaplastic regulation of the threshold for future LTP [8,44-50].”
BackgroundDuman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
NMDA Receptor Subunit Composition Controls Synaptic Plasticity by Regulating Binding to CaMKII
Barria, A., & Malinow, R. (2005) · Neuron · doi:10.1016/j.neuron.2005.08.034 · Cited by 709 · cited 1×
“plasticity believed to be necessary for learning and memory formation [9-18].”
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Shen, K., & Meyer, T. (1999) · Science · doi:10.1126/science.284.5411.162 · Cited by 673 · cited 1×
“plasticity believed to be necessary for learning and memory formation [9-18].”
BackgroundSignaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537 · cited 1×
“Ketamine has been shown to lead to enhanced synaptic glutamate release in the prefrontal cortex [53] suggesting NMDAR activation, and it has been postulated that ketamine may be a blockade of GABAergic interneurons projecting to prefrontal cortical synapses that disinhibit glutamate release, or perhaps blockade of pre…”
BackgroundMcEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svenningsson, P., & Fuchs, E. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.80 · Cited by 406 · cited 1×
“Tianeptine is a unique antidepressant and anxiolytic agent with serotonin reuptake inhibitory activity as well as activity at glutamate receptors [81].”
BackgroundThe BCM theory of synapse modification at 30: interaction of theory with experiment
Cooper, L. N., & Bear, M. F. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3353 · Cited by 395 · cited 1×
“NMDAR activation is a key component of both the induction of LTP and of metaplastic regulation of the threshold for future LTP [8,44-50].”
BackgroundA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Leonard, A. S., Lim, I. A., Hemsworth, D. E., Horne, M. C., & Hell, J. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3239 · Cited by 385
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Self-citationBurgdorf, J., Panksepp, J., & Moskal, J. R. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.11.011 · Cited by 258
Self-citationZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“AZD6765, another weak NMDA channel blocker, demonstrated short-term reduction of depression scores, within 80 min of dosing but lasting < 24 h, without causing increased BPRS+ scores [80].”
BackgroundIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 2×
“Another NR2B-selective antagonist, MK-0657, also reduced secondary efficacy measures by Day 5 of oral administration in 5 subjects without causing psychotomimetic side effects [75].”
BackgroundHippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine
Thompson, L. T., Moskal, J. R., & Disterhoft, J. F. (1992) · Nature · doi:10.1038/359638a0 · Cited by 182
Self-citationA randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177 · cited 1×
“The antidepressant activity of D-cycloserine has been studied in clinical trials, where it was found to not possess antidepressant activity [77], or, in a recent study at higher dose, it has been reported that 2 weeks of daily oral treatment resulted in decreased depression score without psychotomimetic side effects a…”
BackgroundChandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158 · cited 2×
“The Phase IIa study was a randomized, doubleblind, multiple-dose level, placebo-controlled, single IV dose parallel safety and efficacy study of GLYX-13 in subjects with major depressive disorder (MDD) diagnosed using the Structured Clinical Interview for DSM-IV TR Axis I Disorders [62] who had experienced poor respon…”
MethodControlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89 · cited 1×
“The antidepressant activity of D-cycloserine has been studied in clinical trials, where it was found to not possess antidepressant activity [77], or, in a recent study at higher dose, it has been reported that 2 weeks of daily oral treatment resulted in decreased depression score without psychotomimetic side effects a…”
Background
Cited by
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Glutamatergic Mechanisms Associated with Seizures and Epilepsy
Barker-Haliski, M., & White, H. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022863 · Cited by 442
Glutamate: the master neurotransmitter and its implications in chronic stress and mood disorders
Pal, M. M. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.722323 · Cited by 194
Metadata
- Authors
- Moskal, J. R., Burch, R., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhoft, J. F., & Leander, J. D.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2013-11-20
- Volume
- 23
- Issue
- 2
- Pages
- 243-254
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2067937090
- Cited by
- 131
- References
- 32
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.